Association between Lymph Node Status and Expression Levels of Androgen Receptor, miR-185, miR-205, and miR-21 in Breast Cancer Subtypes

Breast cancer is the most commonly diagnosed cancer among women. Difficulties in treating breast cancer are associated with the occurrence of metastases at early stages of disease, leading to its further progression. Recent studies have shown that changes in androgen receptor (AR) and microRNAs' expressions are associated with mammary gland carcinogenesis, in particular, with the formation of metastases. Thus, to identify novel metastatic markers, we evaluated the expression levels of AR; miR-185 and miR-205, both of which have been confirmed to target AR; and miR-21, transcription of which is regulated by AR, in breast cancer samples (n = 89). Here, we show that the molecular subtypes of breast cancer differ in the expression profiles of AR and AR-associated microRNAs. In addition, the expression of AR and these microRNAs may depend on the expression of PR, ER, and HER2 receptors. Our results show that the possibility of using AR and microRNAs as markers depends on the tumor subtype: a decrease in AR expression may be the marker for the presence of lymph node metastases in patients with HER2-positive subtypes of breast cancer, and disturbance of miR-205, miR-185, and miR-21 expressions may be the marker in patients with a luminal B HER2-positive subtype. Cases with metastases in this type of breast cancer are characterized by a higher level of miR-205 and a lower level of miR-185 and miR-21 in tumor tissues compared to nonmetastatic cases. A decrease in the miR-185 level is also associated with lymph node metastasis in luminal B HER2-negative breast cancer. Thus, the expression levels of AR, miR-185, miR-205, and miR-21 can serve as markers to predict cancer spread to the lymph node in luminal B- and HER2-positive subtypes of breast cancer.

[1]  V. Ovchinnikov,et al.  Expression of the miR-190 family is increased under DDT exposure in vivo and in vitro , 2018, Molecular Biology Reports.

[2]  Shinn-Ying Ho,et al.  Identifying a miRNA signature for predicting the stage of breast cancer , 2018, Scientific Reports.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  A. Bilancio,et al.  The Androgen Receptor in Breast Cancer , 2018, Front. Endocrinol..

[5]  Guoxin Zhang,et al.  miR-185-5p inhibits F-actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE , 2018, Molecular medicine reports.

[6]  E. Scarpi,et al.  Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? , 2018, Translational oncology.

[7]  J. Meléndez-Zajgla,et al.  New emerging roles of microRNAs in breast cancer , 2018, Breast Cancer Research and Treatment.

[8]  S. Bose,et al.  Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features , 2018, PloS one.

[9]  L. Tang,et al.  Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study. , 2018, Oncology letters.

[10]  Shaohua Zhang,et al.  Receptor conversion in metastatic breast cancer: a prognosticator of survival , 2016, Oncotarget.

[11]  S. Andò,et al.  Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor , 2016, Oncotarget.

[12]  Peng-ju Zhang,et al.  MicroRNA-185 downregulates androgen receptor expression in the LNCaP prostate carcinoma cell line. , 2015, Molecular medicine reports.

[13]  A. Redig,et al.  Breast cancer as a systemic disease: a view of metastasis , 2013, Journal of internal medicine.

[14]  H. Lilja,et al.  miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients , 2013, British Journal of Cancer.

[15]  S. Fuqua,et al.  The Role of Androgen Receptor in Breast Cancer. , 2012, Drug discovery today. Disease mechanisms.

[16]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Maria Kafousi,et al.  MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer , 2011, Cell cycle.

[18]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Rohit Bhargava,et al.  Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation , 2010, Modern Pathology.

[20]  S. Shenouda,et al.  MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.

[21]  E. Wentzel,et al.  miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. , 2009, Cancer research.

[22]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[23]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[24]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.